$0.22 EPS Expected for Pfenex Inc. (PFNX)
March 13, 2018 – By Darrin Black
Analysts expect Pfenex Inc. (NYSEAMERICAN:PFNX) to report $0.22 EPS on March, 21.They anticipate $0.67 EPS change or 148.89 % from last quarter’s $-0.45 EPS. PFNX’s profit would be $5.18M giving it 5.17 P/E if the $0.22 EPS is correct. After having $-0.37 EPS previously, Pfenex Inc.’s analysts see -159.46 % EPS growth. The stock increased 4.52% or $0.2 during the last trading session, reaching $4.55. About 105,282 shares traded. Pfenex Inc. (NYSEAMERICAN:PFNX) has declined 30.30% since March 13, 2017 and is downtrending. It has underperformed by 47.00% the S&P500.
Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company has market cap of $107.06 million. The Company’s lead product candidates include PF708, a therapeutic equivalent candidate to Forteo for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. It currently has negative earnings. The firm also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia.
More recent Pfenex Inc. (NYSEAMERICAN:PFNX) news were published by: Marketwatch.com which released: “Pfenex Inc.” on June 06, 2016. Also Prnewswire.com published the news titled: “Pfenex To Present at the Cantor Fitzgerald Global Healthcare Conference on …” on September 19, 2017. Prnewswire.com‘s news article titled: “Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide …” with publication date: March 08, 2018 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.